EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...
Histological analysis of the resected specimen diagnosed a Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) with mild lymphocytic submucosal inflammation. Crucially, there was no ...
Non-muscle invasive bladder cancer is cancer that’s only in the inner lining of your bladder. It hasn’t grown into the muscle wall. Your doctor may also call it superficial bladder cancer, urothelial ...
Richard T. Bryan, PhD, Wenyu Liu, PhD, Sarah J. Pirrie, MSc, Rashid Amir, FRCR, Jean Gallagher, Ana I. Hughes, MSc, Kieran P. Jefferson, FRCS, Allen Knight, MBA ...
For individuals facing fear, uncertainty and repeated procedures associated with recurrent low-grade intermediate-risk bladder tumors, timely access to treatment can be critical. ZUSDURI, the first ...
The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...
Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...
“Identifying individuals at high risk for UTIs allows for more targeted treatment and care strategies, thereby enhancing patient safety.” — Yunlan Jiang, Chengdu University of Traditional Chinese ...